STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	0017754	A. BUILDING: _____ B. WING _____	C 02/11/2026

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
SV SOUTH BELOIT EAST	2775 KADLEC DR BELOIT, WI 53511

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
N 000	Initial Comments On 02/11/2026, Surveyor conducted a standard licensure survey and a complaint investigation at SV South Beloit East. One deficiency was identified. One of 1 deficiency was a repeat violation (see Statement of Deficiency (SOD) S66I11, SOD S66I12, SOD S66I13, SOD S66I14 and SOD Z7JO11). Complaint was unsubstantiated. Census: 5	N 000		
N 352	83.32(3)(h) Rights of Residents: Receive medication In addition to the rights under s. 50.09, Stats., each resident shall have all of the following rights: Receive medication. Receive all prescribed medications in the dosage and at intervals prescribed by a practitioner. The resident has the right to refuse medication unless the medication is court ordered. This Rule is not met as evidenced by: Based on observation, record review and interview, the provider did not administer medications in the intervals prescribed by a practitioner for 2 of 2 residents reviewed. This requirement is being cited for a sixth time. See Statement of Deficiency (SOD) S66I11, dated 04/27/2022; SOD S66I12, dated 12/28/2022; SOD S66I13, dated 05/18/2023; SOD S66I14, dated 10/18/2023, and SOD Z7JO11, dated 04/24/2020). Resident 1 did not receive his/her Fluticasone	N 352		

LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE | TITLE | (X6) DATE

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	0017754	A. BUILDING: _____ B. WING _____	C 02/11/2026

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
SV SOUTH BELOIT EAST	2775 KADLEC DR BELOIT, WI 53511

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
N 352	Continued From page 1	N 352		

(nasal spray), Latanoprost (eye drops) and Cephalexin (antibiotic) as prescribed.
Resident 2 received his/her Basaglar (insulin) after the expiration date.

Findings Include:

Example 1: Resident 1

On 02/11/2026, at approximately 12:30 PM, Surveyor observed Resident 1's medications in the med cart. Surveyor observed a bottle of Fluticasone, with an open date of 12/01/2025; a bottle of Latanoprost, with a start date of 10/30/2025; and blister cards of Cephalexin with a start date of 02/03/2026.

On 02/11/2026, Surveyor reviewed Resident 1's record.

Resident 1 admitted to the facility, 10/04/2013, with diagnoses including diabetes and glaucoma.

-Resident 1's Medication Administration Records (MARs), dated 12/01/2025 to 02/11/2026, documented:
"Fluticasone Prop (propionate) 50 MCG (micrograms) Spray - Instill 1 spray in Nostrils 2 times daily."
The MARs documented the medication had been administered as prescribed.
The bottle of Fluticasone only contained a 30-day supply (4 sprays per day divided by 120 actuations = 30)

On 02/11/2026, at approximately 4:15 PM, Surveyor interviewed Administrator A and Manager B. Surveyor reviewed Resident 1's MARs with Administrator A and Manager B and asked for verification if Resident 1 received

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	0017754	A. BUILDING: _____ B. WING _____	C 02/11/2026

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
SV SOUTH BELOIT EAST	2775 KADLEC DR BELOIT, WI 53511

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
N 352	Continued From page 2	N 352		

his/her Fluticasone as prescribed. Administrator A and Manager B confirmed the bottle of Fluticasone was only a 30-day supply and there were no other bottles available. Administrator A stated staff would be re-educated on med administration to ensure residents received prescribed medications.

"Each bottle contains a net fill weight of 16 g (grams) and will provide 120 actuations. Each actuation delivers 50 mcg (micrograms) of fluticasone propionate in 100 mg (milligram) of formulation through the nasal adapter. The correct amount of medication in each spray cannot be assured after 120 sprays even though the bottle is not completely empty." (Source: National Institute of Health website, Fluticasone Propionate, 12/2022, https://dailymed.nlm.nih.gov/dailymed/fda (retrieval date - July 24, 2024).)

-Resident 1's MARs, dated 12/01/2025 to 02/11/2026, documented:
Latanoprost 0.005% eye drops (Xalatan) - Instill 1 drop into both eyes daily at bedtime for glaucoma. Start Date: 10/09/2025.
The MARs documented the medication had been administered 70 out of 72 opportunities.
The medication should have been replaced 6 weeks after the start date of 10/30/2025, approximately December 11, 2025.

On 02/11/2026, at approximately 4:15 PM, Surveyor interviewed Administrator A and Manager B. Surveyor asked for clarification on how long the bottle of Latanoprost was good for once it was opened. Manager B stated s/he was utilizing the expiration date printed on the bottle by the manufacturer. Manager B stated s/he had a list that provided guidance on what the 'new'

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	0017754	A. BUILDING: _____ B. WING _____	C 02/11/2026

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
SV SOUTH BELOIT EAST	2775 KADLEC DR BELOIT, WI 53511

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
N 352	Continued From page 3	N 352		

expiration dates were for eye drops once they were opened and would utilize it. Manager B stated Resident 1 only had the one bottle of Latanoprost, and [1] had received expired eye drops and s/he would reorder a new bottle immediately.

"Unopened bottles should be stored in the refrigerator. Once opened, the bottle can be kept at room temperature for either 6 weeks (Xalatan) or 30 days (Iyuzeh). For Xelpros, the bottle should continue to be kept in the refrigerator, even after opening, until the expiration date on the bottle." (Source: MedlinePlus website, Latanoprost Ophthalmic, August 15, 2023, https://medlineplus.gov/druginfo/meds/a697003.html (retrieval date - January 22, 2025).)

-Resident 1's MARs, dated 2/01/2026 to 02/11/2026, documented:
"Cephalexin 500 MG (milligram) capsule (Keflex) - Take 1 capsule by mouth 4 times daily for 10 days for suspected UTI (urinary tract infection)."
Scheduled at 8:00 AM, 12:00 PM, 4:00 PM, and 8:00 PM.
The MAR documented the medication was started 02/04/2026 at 11:05 AM.

8:00 AM blister card had 3 of 10 capsules remaining; started 02/05/2026
12:00 PM blister card had 2 of 10 capsules remaining; started 02/04/2026
4:00 PM blister card had 5 of 10 capsules remaining; started 02/04/2026; should only had 3 capsules remaining
8:00 PM blister card had 3 of 10 capsules remaining; started 02/04/2026

On 02/11/2026, at approximately 4:15 PM, Surveyor interviewed Administrator A and

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	0017754	A. BUILDING: _____ B. WING _____	C 02/11/2026

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
SV SOUTH BELOIT EAST	2775 KADLEC DR BELOIT, WI 53511

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
N 352	Continued From page 4 Manager B. Surveyor asked for clarification as to when Resident 1's Cephalexin was delivered to the facility. Manager B contacted the pharmacy who confirmed the medication had been delivered in time for the 4:00 PM dose on 02/03/2026. Manager B reviewed Resident 1's MAR and confirmed that the antibiotic was not administered until the noon dose on 02/04/2026. Manager B stated there was one extra capsule for the 4:00 PM dose due to the medication not being adminsitered when it was delivered and s/he could not explain why there was another extra capsule. Administrator A and Manager B stated they would continue to re-educate staff on proper medication administration. Example 2: Resident 2 On 02/11/2026, at approximately 12:30 PM, Surveyor observed Resident 2's medications in the med cart. Surveyor a Basaglar pen with a handwritten open date of 01/02/2026 and a handwritten expiration date of 28. On 02/11/2026, Surveyor reviewed Resident 2's record. Resident 2 admitted to the facility, 05/06/2022, with diagnosis including diabetes. Resident 2's MARs, dated 01/01/2026 to 02/11/2026, documented: "Basaglar 100 Unit / ML (milliliter) Kwikpen - Inject 25 Units under the skin in the morning for Type 2 diabetes - Give 12 Units only if blood sugar is less than 90." On 02/11/2026, at approximately 4:0 PM, Surveyor interviewed Manager B. Surveyor showed Manager B the Kwikpen which had an	N 352		

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:	(X2) MULTIPLE CONSTRUCTION	(X3) DATE SURVEY COMPLETED
	0017754	A. BUILDING: _____ B. WING _____	C 02/11/2026

NAME OF PROVIDER OR SUPPLIER	STREET ADDRESS, CITY, STATE, ZIP CODE
SV SOUTH BELOIT EAST	2775 KADLEC DR BELOIT, WI 53511

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
N 352	Continued From page 5 open date of 01/02/2026. Surveyor asked if the Basaglar Kwikpen was to be utilized after being opened for 28 days. Manager B stated the pen should have been removed from the med cart and would re-educate staff. "Unused Pens: Store unused Pens in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze BASAGLAR. Do not use if it has been frozen. Unused Pens may be used until the expiration date printed on the Label, if the Pen has been kept in the refrigerator. In-use Pen: Store the Pen you are currently using at room temperature [up to 86°F (30°C)] and away from heat and light. Throw away the Pen you are using after 28 days, even if it still has insulin left in it." (Source: Eli Lilly and Company website, BASAGLAR KWIKPEN - insulin glargine injection, solution, 11/2023, https://uspl.lilly.com/basaglar/basaglar.html#ug0 (retrieval date - February 15, 2026).)	N 352		